Notice to Clarify the Types of Clinical Trials NIBIB Will Support Under PAR-18-206 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

Notice Number: NOT-EB-18-002

Key Dates
Release Date:   December 14, 2017

Related Announcements

Issued by
National Institute of Biomedical Imaging and Bioengineering (NIBIB)


The purpose of this Notice is to clarify the types of clinical trials that NIBIB will support under the Funding Opportunity Announcement (FOA)PAR-18-206 , Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional).
For NIBIB assigned applications submitted to this FOA that propose clinical trials, NIBIB will only support applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility, or other small clinical trials that inform the early-stage technology development in the submitted application. NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials, or trials in which the primary outcome is efficacy, effectiveness, or a post-market concern.

Applicants are strongly encouraged to contact NIBIB Program staff  or the Scientific/Research contact for this FOA for guidance in advance of submitting an application to ensure their proposed project is in compliance with new NIH human subjects research and clinical trials policies ( and consistent with the types of clinical trial projects that NIBIB supports.


Please direct all inquiries to:

Michael Wolfson, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-4778